UK CMO appoints new director
![](/46/pdcnewsitem/03/78/17/symbiosis.png)
Sterile manufacturing specialist Symbiosis Pharmaceutical Services has appointed Joanne Anderson as its new Business Development Director to help drive its commercial growth.
Symbiosis Pharmaceutical Service has promoted Mrs Anderson to the role following three successful years with the Scotland-based pharmaceutical contract manufacturing organisation (CMO) and will join the management team.
Reporting to the CEO, her responsibilities will include the strategic and operational management of all sales and marketing activities for Symbiosis globally.
A qualified analytical chemist with an MBA, Mrs Anderson has worked in the biopharmaceutical outsourcing sector for almost 15 years and has spent the last 8 years specialising in the field of sterile injectable products for clinical trials and low volume commercial supply.
Colin MacKay, CEO at Symbiosis Pharmaceutical Services, said: “Joanne has made an increasingly valuable contribution to the commercial team over the last few years in terms of generating market awareness of the world-class services offered by Symbiosis and her highly professional approach to successfully achieving significant year-on-year sales revenue growth.
“As we look to further expand the business, it’s essential for us to have a management team comprising knowledgeable, high-performing and well-respected industry professionals in key senior roles. Our decision to appoint Joanne as our Business Development Director aligns perfectly with that.”
Symbiosis recently announced plans to expand its sterile filling facility following increased demand for its small-scale sterile manufacturing services and to ensure continued compliance with the latest interpretation of the guidelines by the MHRA.
Mrs Anderson said: “We are at a very important stage of the company’s development so I am delighted and honoured to have been promoted into this new role to drive the commercial development of the company and take Symbiosis to the next level.
“Recent investments into our facility enable us to aseptically manufacture and provide lyophilization services at both the clinical stage and for clients with niche licensed products.
“My job is to ensure potential and existing clients know that we are not only a safe pair of hands from a technical and quality perspective, but that we are time focussed in our approach to the cGMP manufacture of drug products to ensure tight timelines are met.
“It’s also important that our customers understand that our strength comes from our focus on exceeding client expectations and delivering a world-class service," added Mrs Anderson.
Symbiosis specialises in the sterile fill/finish of biologic and small molecule products into vials, which are either liquid or lyophilised formulations. The fast-growing CMO’s capabilities include the ability to handle and fill antibodies, proteins, peptides, nucleic acids, cytotoxic, cytostatic and highly potent APIs including ADCs along with conventional small molecules.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance